Volition and Hologic announced a partnership to co-market Volition’s Nu.Q Discover epigenetic profiling service via Hologic’s Diagenode business. The service utilizes nucleosome quantification technology to aid drug developers and researchers in biomarker development during preclinical and clinical phases. Financial terms were undisclosed, but the agreement aims to expand access within a $200 million market, strengthening Volition's presence in pharmaco-epigenetics and enhancing precision medicine efforts for clients of both companies.